Recruitment of people aged 55 - 90 to take part in the final-stage study in the US is taking place. The study will examine if the drug solanezumab slows the cognitive and functional decline of people who suffer from mild Alzheimer's.
In the new trial expected to end by December 2016, people are going to be given solanezumab as a monthly 400mg injection for 18 months.
Dr Eric Karran, director of research at Alzheimer's Research UK, said that the results would suggest that monthly injections should be given early to ward off the disease, News.com.au reported.
Dr Karran said that the drug showed "reasonable" effect in people suffering from mild Alzheimer's and results would come within five years.
--ANI (Posted on 05-12-2013)